THERAPEUTIC EFFECTS OF GENETICALLY ENGINEERED TOXIN (DAB486IL-2) IN PATIENT WITH CHRONIC LYMPHOCYTIC-LEUKEMIA

被引：33
作者：
LEMAISTRE, CF
ROSENBLUM, MG
REUBEN, JM
PARKINSON, DR
MENEGHETTI, CM
PARKER, K
SHAW, JP
DEISSEROTH, AB
WOODWORTH, T
机构：
[1] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77025
[2] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,HOUSTON,TX 77025
[3] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT LAB MED,HOUSTON,TX 77025
[4] NCI,BETHESDA,MD 20892
[5] SERAGEN INC,HOPKINTON,MA
来源：
LANCET | 1991年 / 337卷 / 8750期
关键词：
D O I：
10.1016/0140-6736(91)92788-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In DAB486IL-2 the receptor-binding domain of native diphtheria toxin is replaced by human IL-2 sequences. This recombinant fusion protein is selectively cytotoxic for cells bearing high-affinity IL-2 receptors-eg, leukaemic cells. A patient with chronic lymphocytic leukaemia who did not respond to gamma interferon and conventional antileukaemic drugs has responded to DAB486IL-2.
引用
收藏
页码：1124 / 1125
页数：2
相关论文
共 9 条
1